Financial Review: Lipella Pharmaceuticals (LIPO) & The Competition

Lipella Pharmaceuticals (NASDAQ:LIPO) is one of 1,047 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Lipella Pharmaceuticals to related companies based on the strength of its earnings, dividends, analyst recommendations, valuation, institutional ownership, risk and profitability.

Profitability

This table compares Lipella Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-882.82%	-192.33%	-154.24%
Lipella Pharmaceuticals Competitors	-3,620.42%	-274.38%	-33.56%

Institutional & Insider Ownership

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Lipella Pharmaceuticals has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals’ rivals have a beta of 0.79, suggesting that their average stock price is 21% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Lipella Pharmaceuticals and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0	0	1	0	3.00
Lipella Pharmaceuticals Competitors	7584	20844	48449	1189	2.55

Lipella Pharmaceuticals presently has a consensus price target of $16.00, indicating a potential upside of 563.90%. As a group, “Pharmaceutical preparations” companies have a potential upside of 73.37%. Given Lipella Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Lipella Pharmaceuticals is more favorable than its rivals.

Earnings and Valuation

This table compares Lipella Pharmaceuticals and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lipella Pharmaceuticals	$483,533.00	-$4.62 million	-0.57
Lipella Pharmaceuticals Competitors	$2.55 billion	$151.16 million	-5.57

Lipella Pharmaceuticals’ rivals have higher revenue and earnings than Lipella Pharmaceuticals. Lipella Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Lipella Pharmaceuticals beats its rivals on 8 of the 13 factors compared.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.